

<u>Short Name</u>	<u>Comments</u>	<u>Type</u>	<u>Investigator</u>	<u>Contact</u>
2019-362: Melanoma Surveillance	A Prospective Standardized Surveillance of Early-Stage Cutaneous Melanoma Based on Anatomic Stage and Molecular Profiling	Other	<b>SHORE:</b> Dr. G. Paul Wright	<b>Zak Mulder</b> zachary.mulder@spectrumhealth.org (616) 391-2724
EA6194	EA6194: Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EA6141	Phase II/III Trial for STAGE III/IV/Unresectable Melanoma; <u>Nivolumab</u> + <u>Ipilimumab</u> + <u>Sargramostim</u> versus <u>Nivolumab</u> + <u>Ipilimumab</u>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
A091802	Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EA6134	A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
S1801	A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>

---

ARRAY-818-201	<b>An Open-label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients with BRAFV600-mutant Melanoma Brain Metastasis</b>	Treatment	<b>CHCWM</b> Physician Investigators	CHCWM (616) 954-9800 <a href="http://www.chcwm.com">www.chcwm.com</a>
Regeneron	<b>REGN3767-ONC-1613: A Phase I, Open-Label, Dose-Escalation and Cohort Expansion First-in-human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Lag 3 Inhibitor) Administered Alone or in Combination with REGN2810 (PD-1 Inhibitor) in Patients with Advanced Malignancies</b>	Treatment	<b>START Midwest</b> Investigators	START Midwest (616) 954-5554

---